| Abstract |
THERAPEUTIC ADVANCES IN HER2+ BREAST CANCER. 58,000 new cases of breast cancer occured in France in 2018, of which 15-20% are HER2-positive. HER2-targeted therapies deeply modified the management of these tumors, first by the introduction of monoclonal antibodies such as trastuzumab and pertuzumab and tyrosine kinase inhibitors such as tucatinib, and more recently by antibody drug conjugates (ADC), with trastuzumab-deruxtecan in the forefront. In the localized stage, neoadjuvant chemotherapy associated with trastuzumab is now the standard strategy, allowing the adjuvant strategy to be adapted to the therapeutic response, with the use of another ADC, T-DM1, in the absence of pathological complete response. These various therapeutic advances have led to a significant improvement in the prognosis of HER2-positive breast cancer, whether at the metastatic or localized stage. |
Institut de Recherche en Cancérologie de
